19 min listen
Monoclonal Antibodies Targeting Amyloid for Alzheimer Disease
Monoclonal Antibodies Targeting Amyloid for Alzheimer Disease
ratings:
Length:
29 minutes
Released:
Aug 3, 2023
Format:
Podcast episode
Description
In this interview, dementia expert Gil D. Rabinovici, MD, discusses monoclonal antibodies that target beta-amyloid–-including a recent phase 3 trial of donanemab published in JAMA-–and reviews considerations for their use in patients with Alzheimer disease. Related Content: Amyloid-Targeting Monoclonal Antibodies for Alzheimer Disease Donanemab in Early Symptomatic Alzheimer Disease
Released:
Aug 3, 2023
Format:
Podcast episode
Titles in the series (100)
Explaining the Improved Health of the US: Mortality Trends 1969-2013: Interview with Ahmedin Jemal, DVM, PhD, author of , and J. Michael McGinnis, MD, MPP, author of . Also in this episode is a conversation with Christopher J.L. Murray, MD, DPhil, a Professor of Global Health at the University of Washington and... by JAMA Clinical Reviews